Survivin promoter-driven adenovirus early region 1A (E1A) gene (Survivin-E1A)

The Survivin promoter controlling viral E1A gene expression is a genetic regulatory system designed for conditionally replicative adenoviruses (CRAds) in cancer therapy. Survivin, a member of the inhibitor of apoptosis (IAP) family encoded by the BIRC5 gene, is highly expressed in most human cancers but is nearly absent in normal adult tissues (Ambrosini et al., 1997). By placing the essential viral replication gene E1A under the control of the Survivin promoter, the adenovirus is engineered to replicate specifically in malignant cells (Kamizono et al., 2001). This tumor-selective replication leads to the direct lysis of cancer cells, a process known as oncolysis, while minimizing damage to healthy surrounding tissues (Ulasov et al., 2007). This approach is being investigated for various solid tumors, including glioma, lung, and bladder cancers (Zhu et al., 2004). Key therapeutic challenges include the host's immune response to the adenovirus vector and the potential for low-level E1A expression in normal cells where the promoter might be slightly active (Berk, 2005).

Other names

BIRC5 promoter-driven E1ASurvivin-responsive E1AAd-Sur-E1ASurvivin-driven E1A expression system

The system utilizes the tumor-specific activity of the Survivin promoter to drive the expression of the adenovirus E1A gene, which is essential for viral replication. This results in selective viral multiplication within cancer cells, leading to oncolysis (cell lysis) and the release of new virions to infect adjacent tumor cells, while sparing normal cells that lack Survivin promoter activity.